Table 3.
Classification and characteristics of clinical trials on cell therapy in China.
| Items | Classification | CAR n (%) | TCR n (%) | Vaccine n (%) | Stem n (%) | Other n (%) | Total n (%) |
|---|---|---|---|---|---|---|---|
| Phase | I | 36 (60.0) | 16 (80.0) | 1 (16.7) | 0 | 12 (23.1) | 65 (46.4) |
| I/II | 22 (36.7) | 3 (15.0) | 1 (16.7) | 1 (50.0) | 14 (26.9) | 41 (29.3) | |
| II | 2 (3.3) | 1 (5.0) | 3 (50.0) | 1 (50.0) | 22 (42.3) | 29 (20.7) | |
| III/IV/other | 0 | 0 | 1 (16.7) | 0 | 4 (7.7) | 5 (3.6) | |
| Trial status | Open | 40 (66.7) | 13 (65.0) | 2 (33.3) | 1 (50.0) | 18 (34.6) | 74 (52.8) |
| Closed | 6 (10.0) | 1 (5.0) | 0 | 0 | 12 (23.1) | 19 (13.6) | |
| Completed | 14 (23.3) | 6 (30.0) | 4 (66.7) | 1 (50.0) | 22 (42.3) | 47 (33.6) | |
| Totally (n/140*%) | 60 (42.9) | 20 (14.3) | 6 (4.3) | 2 (1.4) | 52 (37.1) | 140 (100) | |
| Tumor types top 5 | Liver | 12 (20.0) | 9 (45.0) | 4 (66.7) | 0 | 12 (23.1) | 37 (26.4) |
| Pancreas | 9 (15.0) | 3 (15.0) | 1 (16.7) | 0 | 17 (32.7) | 30 (21.4) | |
| Lung | 15 (25.0) | 0 | 3 (50.0) | 0 | 9 (17.3) | 27 (19.3) | |
| Gastric | 7 (11.7) | 3 (15.0) | 1 (16.7) | 1 (50.0) | 7 (13.5) | 19 (13.6) | |
| Esophageal | 14 (23.3) | 0 | 0 | 0 | 4 (7.7) | 18 (12.9) | |
| Unspecified solid tumor | 11 (18.3) | 3 (15.0) | 1 (16.7) | 0 | 4 (7.7) | 19 (13.6) | |
| Primary endpoint | Safety | 48 (80.0) | 17 (85.0) | 2 (33.3) | 1 (50.0) | 16 (30.8) | 84 (60.0) |
| Efficacy | 12 (20.0) | 3 (15.0) | 4 (66.7) | 1 (50.0) | 36 (69.2) | 56 (40.0) | |
| Patient population | Biomarker selected | 13 (21.7) | 7 (35.0) | 0 | 0 | 7 (13.5) | 8 (19.3) |
| Unselected | 47 (78.3) | 13 (65.0) | 6 (100) | 2 (100) | 45 (86.5) | 113 (80.7) |
NA, not applicable/available.